Ligandal Inc

Ligandal Inc. is a privately held company based in San Francisco, California. With 13 employees, Ligandal is a relatively small company that generates $5.2 million in annual revenue. Ligandal is a genetic medicine company specializing in the development of targeted and personalized therapies using nanotechnology. They focus on creating ultra-rapid therapeutics and vaccines for outbreaks and pandemics, as well as working in the fields of immuno-oncology and rare genetic diseases. Currently, their primary focus is on developing a peptide-based cure for the COVID-19 pandemic. Ligandal's technology centers around combining gene therapy with targeting peptides to create new approaches in evolutionary medicine. They utilize a peptide nanoscaffold based approach for treating COVID-19, aiming to develop a combined antidote-vaccine. Their expertise spans targeted gene delivery, nano- and biomaterials, computational modeling of peptides, binding simulations, immunoengineering, and CRISPR and TALEN based gene editing. Ligandal Inc. can be reached via their website at ligandal.com.